A single infusion of a genetically reprogrammed immune cell therapy produced confirmed cancer-free survival in more than one-third of large B-cell lymphoma patients and nearly half of follicular ...

PHILADELPHIA (WPVI) -- Skin rashes can be a real nuisance, but they're generally benign. However, there is one time when that incessant itching can be a sign of something more serious. "This tends to ...

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel ...

Ten-year results show a single CAR T infusion can keep many patients with aggressive and slow-growing B-cell lymphomas cancer-free, pointing toward true long-term cures.

A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, ...

Approximately 30%-50% of patients with relapsed or refractory B-cell non-Hodgkin lymphomas have achieved durable remissions with CAR T-cell therapies targeting CD19 over follow-up periods of up to 5 ...

Almost a third of patients with aggressive lymphoma remained cancer free 10 years after treatment with CAR T-cell therapy. The long-term data indicate that CD19-directed CAR T-cell therapy may cure ...

Anaplastic large cell lymphoma is a rare type of non-Hodgkin lymphoma that primarily affects T cells. While most cases respond well to conventional chemotherapy, achieving long-term survival rates as ...